Lapatinib and chronic renal insufficiency

Abstract

Lapatinib is an intracellular tyrosine-kinase inhibitor of both EGFR (ErbB1) and HER2 (ErbB2) receptors, which is indicated in the treatment of metastatic disease pretreated with anti-HER2 therapies. We report the clinical case of a woman with chronic renal failure in dialysis affected by HER2-positive metastatic breast neoplasia and treated with lapatinib and letrozole (Oncology).

Keywords

• Lapatinib
• breast cancer
• metastatic breast cancer
• HER2